XML 109 R54.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Segment Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2016
Segment Reporting [Abstract] |
Revenue by product |
| For the Years Ended December 31,
| 2016 |  | 2015 |  | 2014
(In millions) | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 3,169.4 |  |  | $ | 798.7 |  |  | $ | 3,968.1 |  |  | $ | 2,908.2 |  |  | $ | 730.2 |  |  | $ | 3,638.4 |  |  | $ | 2,426.6 |  |  | $ | 482.6 |  |  | $ | 2,909.2 |
AVONEX | 1,675.3 |  |  | 638.2 |  |  | 2,313.5 |  |  | 1,790.2 |  |  | 840.0 |  |  | 2,630.2 |  |  | 1,956.7 |  |  | 1,056.4 |  |  | 3,013.1 |
PLEGRIDY | 305.0 |  |  | 176.7 |  |  | 481.7 |  |  | 227.1 |  |  | 111.4 |  |  | 338.5 |  |  | 27.8 |  |  | 16.7 |  |  | 44.5 |
TYSABRI | 1,182.9 |  |  | 780.9 |  |  | 1,963.8 |  |  | 1,103.1 |  |  | 783.0 |  |  | 1,886.1 |  |  | 1,025.1 |  |  | 934.4 |  |  | 1,959.5 |
FAMPYRA | — |  |  | 84.9 |  |  | 84.9 |  |  | — |  |  | 89.7 |  |  | 89.7 |  |  | — |  |  | 80.2 |  |  | 80.2 |
ZINBRYTA | — |  |  | 7.8 |  |  | 7.8 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Hemophilia: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ELOCTATE | 445.2 |  |  | 68.0 |  |  | 513.2 |  |  | 308.3 |  |  | 11.4 |  |  | 319.7 |  |  | 58.4 |  |  | — |  |  | 58.4 |
ALPROLIX | 268.0 |  |  | 65.7 |  |  | 333.7 |  |  | 208.9 |  |  | 25.6 |  |  | 234.5 |  |  | 72.1 |  |  | 3.9 |  |  | 76.0 |
Other product revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 45.9 |  |  | 45.9 |  |  | — |  |  | 51.4 |  |  | 51.4 |  |  | — |  |  | 62.5 |  |  | 62.5 |
SPINRAZA | 4.6 |  |  | — |  |  | 4.6 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
BENEPALI | — |  |  | 100.6 |  |  | 100.6 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
FLIXABI | — |  |  | 0.1 |  |  | 0.1 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total product revenues | $ | 7,050.4 |  |  | $ | 2,767.5 |  |  | $ | 9,817.9 |  |  | $ | 6,545.8 |  |  | $ | 2,642.7 |  |  | $ | 9,188.5 |  |  | $ | 5,566.7 |  |  | $ | 2,636.7 |  |  | $ | 8,203.4 |
Geographic information |
December 31, 2016 (In millions) | U.S. |  | Europe(1) |  | Germany |  | Asia |  | Other |  | Total
Product revenues from external customers | $ | 7,050.4 |  |  | $ | 1,533.5 |  |  | $ | 703.7 |  |  | $ | 217.3 |  |  | $ | 313.0 |  |  | $ | 9,817.9 |
Revenues from anti-CD20 therapeutic programs | $ | 1,249.5 |  |  | $ | 1.9 |  |  | $ | — |  |  | $ | — |  |  | $ | 63.1 |  |  | $ | 1,314.5 |
Other revenues from external customers | $ | 224.7 |  |  | $ | 70.0 |  |  | $ | 1.5 |  |  | $ | 20.2 |  |  | $ | — |  |  | $ | 316.4 |
Long-lived assets | $ | 1,272.3 |  |  | $ | 1,219.3 |  |  | $ | 1.8 |  |  | $ | 7.0 |  |  | $ | 1.4 |  |  | $ | 2,501.8 |
December 31, 2015 (In millions) | U.S. |  | Europe(1) |  | Germany |  | Asia |  | Other |  | Total
Product revenues from external customers | $ | 6,545.8 |  |  | $ | 1,497.6 |  |  | $ | 668.1 |  |  | $ | 143.7 |  |  | $ | 333.3 |  |  | $ | 9,188.5 |
Revenues from anti-CD20 therapeutic programs | $ | 1,269.8 |  |  | $ | 3.5 |  |  | $ | — |  |  | $ | — |  |  | $ | 65.9 |  |  | $ | 1,339.2 |
Other revenues from external customers | $ | 142.0 |  |  | $ | 29.6 |  |  | $ | 1.6 |  |  | $ | 62.9 |  |  | $ | — |  |  | $ | 236.1 |
Long-lived assets | $ | 1,296.5 |  |  | $ | 879.4 |  |  | $ | 2.3 |  |  | $ | 7.7 |  |  | $ | 1.7 |  |  | $ | 2,187.6 |
December 31, 2014 (In millions) | U.S. |  | Europe(1) |  | Germany |  | Asia |  | Other |  | Total
Product revenues from external customers | $ | 5,566.7 |  |  | $ | 1,383.9 |  |  | $ | 811.8 |  |  | $ | 112.8 |  |  | $ | 328.2 |  |  | $ | 8,203.4 |
Revenues from anti-CD20 therapeutic programs | $ | 1,117.1 |  |  | $ | 7.7 |  |  | $ | — |  |  | $ | — |  |  | $ | 70.6 |  |  | $ | 1,195.4 |
Other revenues from external customers | $ | 212.6 |  |  | $ | 31.6 |  |  | $ | 1.8 |  |  | $ | 58.5 |  |  | $ | — |  |  | $ | 304.5 |
Long-lived assets | $ | 1,055.5 |  |  | $ | 701.9 |  |  | $ | 2.5 |  |  | $ | 2.6 |  |  | $ | 3.2 |  |  | $ | 1,765.7 |

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration